Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Safety Evaluation of the Hybrid Closed Loop (HCL) System in Pediatric Subjects With Type 1 Diabetes

24 januari 2022 bijgewerkt door: Medtronic Diabetes
This study is a single-arm, multi-center, Home and Hotel Clinical Investigation in pediatric subjects with type 1 diabetes on insulin pump therapy. The purpose of this study is to demonstrate that the closed loop algorithm is safe as part of the overall system, and to assess the PLGM feature in 7-13 years old subjects.

Studie Overzicht

Toestand

Voltooid

Conditie

Interventie / Behandeling

Gedetailleerde beschrijving

The study will proceed as follows:

Run-in Period - General:

A total of up to 200 subjects (age 2-13) will be enrolled at up to 15 investigational centers (14 in the US, 1 EMEA) in order to reach 120 subjects who will complete the HCL study.

Study Period - At Home:

Following the two week run-in period using the Study Pump (670G), all subjects (age 2-13) will participate in a 3-month study period.

Study Period - Hotel Study Subjects (age 7-13) will participate in a Hotel study (6 days, 5 nights), with the remainder of the study period to be spent at home. Subjects 2-6 years of age are not required to participate in a hotel study. Instead, they will participate in an out-of-home study for 5 consecutive days, 4-6 hours per day.

Continued Access Program Subjects will be given the opportunity to extend use of their study devices for a period of up to 3 years . If subjects choose to participate in the continuation period, they will retain the study devices at the end of study period visit or receive them back in the event they have been returned to study staff already.

Studietype

Ingrijpend

Inschrijving (Werkelijk)

151

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

      • Tel Aviv, Israël
        • Sheba medical center
    • California
      • Escondido, California, Verenigde Staten, 92025
        • AMCR Institute
      • Palo Alto, California, Verenigde Staten, 94305
        • Stanford Hospital and Clinics
      • Torrance, California, Verenigde Staten, 90505
        • SoCal Diabetes
    • Colorado
      • Aurora, Colorado, Verenigde Staten, 80045
        • Barbara Davis Center
    • Florida
      • Jacksonville, Florida, Verenigde Staten, 32207
        • Nemours Children's Clinic
      • Tampa, Florida, Verenigde Staten, 33620
        • University of South Florida - USF Health
    • Georgia
      • Atlanta, Georgia, Verenigde Staten, 30318
        • Atlanta Diabetes Associates
    • Idaho
      • Idaho Falls, Idaho, Verenigde Staten, 83404
        • Rocky Mountain Diabetes and Osteoporosis Center
    • Indiana
      • Indianapolis, Indiana, Verenigde Staten, 46202
        • Indiana University
    • Michigan
      • Ann Arbor, Michigan, Verenigde Staten, 48109
        • University of Michigan

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

2 jaar tot 13 jaar (Kind)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

General Inclusion Criteria

  1. Subject is age 2-13 years at time of screening
  2. Subject has a clinical diagnosis of type 1 diabetes for 1 year or more as determined via medical record or source documentation by an individual qualified to make a medical diagnosis
  3. Subject age 2-6 years has a clinical diagnosis of type 1 diabetes for 3 months or more as determined via medical record or source documentation by an individual qualified to make a medical diagnosis

    Study-specific inclusion criteria

  4. Subject must have a minimum daily insulin requirement (Total Daily Dose) of greater than or equal to 8 units
  5. Subjects 7-13: Subjects and their parent(s)/guardian(s) are willing to participate in an overnight visit at the end of the run-in period.
  6. Subject 7-13 years of age and their parent(s)/guardian(s) are willing to participate in a hotel study for the specified duration of hotel stay.
  7. Subject 2-6 years of age and their parent(s)/guardian(s) are willing to participate in an extended visit during the study period to perform Frequent Sample Testing.
  8. Subject must have companion 18 years or older who will sleep in the same dwelling place every night during the study period. This requirement may be verified by subject report at screening visit.
  9. Subject is willing to perform ≥ 4 finger stick blood glucose measurements daily
  10. Subject is willing to perform required sensor calibrations
  11. Subject is willing to wear the system continuously throughout the study
  12. Subject has a Glycosylated hemoglobin (A1C) value less than 10.0% (as processed by Central Lab) at time of screening visit Note: All HbA1C blood specimens will be sent to and tested by a NGSP certified Central Laboratory. A1C testing must follow National Glycohemoglobin Standardization Program (NGSP) standards.
  13. Subject has TSH in the normal range OR if the TSH is out of normal reference range the Free T3 is below or within the lab's reference range and Free T4 is within the normal reference range.
  14. Subject 7 -13 years of age has had pump therapy for greater than 6 months prior to screening (with or without CGM experience)
  15. Subject 2-6 years of age has had pump therapy for greater than 90 days prior to screening (with or without CGM experience)
  16. Subjects and their parent(s)/guardian(s) are willing to upload data from the study pump; must have Internet access and a computer system that meets the requirements for uploading the study pump
  17. If subject has celiac disease, it has been adequately treated as determined by the investigator
  18. Subjects and their parent(s)/guardian(s) are willing to take one of the following insulins and can financially support the use of either of the 2 insulin preparations throughout the course of the study (i.e. co-payments for insulin with insurance or able to pay full amount)

    • Humalog® (insulin lispro injection)
    • NovoLog® (insulin aspart)
  19. Subjects and their parent(s)/guardian(s)/companions must be able to speak and be literate in English as verified by the investigator

Exclusion Criteria:

  1. Subject has a history of 2 or more episodes of severe hypoglycemia, which resulted in any the following during the 6 months prior to screening:

    1. Medical assistance (i.e. Paramedics, Emergency Room ( ER) or Hospitalization)
    2. Coma
    3. Seizures
  2. Subject is unable to tolerate tape adhesive in the area of sensor placement
  3. Subject has any unresolved adverse skin condition in the area of sensor placement (e.g., psoriasis, dermatitis herpetiformis, rash, Staphylococcus infection)
  4. Females who are sexually active and able to conceive will be excluded if they are not using an effective method of contraception and do not agree to continue using an effective method of contraception for the duration of the study as determined by investigator.
  5. Subject has a cardiovascular condition which the investigator determines should exclude the subject, i.e. ventricular rhythm disturbance, hypertrophic cardiomyopathy
  6. Subject is being treated for hyperthyroidism at time of screening
  7. Subject has diagnosis of adrenal insufficiency
  8. Subject 7-13 years of age has had DKA in the 6 months prior to screening visit.
  9. Subject 2-6 years of age has had DKA in the 3 months prior to screening visit
  10. Subject has taken any oral, injectable, or intravenous (IV) glucocorticoids within 8 weeks from time of screening visit, or plans to take any oral, injectable, or IV glucocorticoids during the course of the study
  11. Subject is actively participating in an investigational study (drug or device) wherein he/she has received treatment from an investigational study drug or investigational study device in the last 2 weeks
  12. Subject 7-13 years of age has been hospitalized or has visited the ER in the 6 months prior to screening resulting in a primary diagnosis of uncontrolled diabetes
  13. Subject 2-6 years of age has been hospitalized or has visited the ER in the 3 months prior to screening resulting in a primary diagnosis of uncontrolled diabetes
  14. Subject is currently abusing illicit drugs
  15. Subject is currently abusing marijuana.
  16. Subject is currently abusing prescription drugs
  17. Subject is currently abusing alcohol
  18. Subject is using pramlintide (Symlin), DPP-4 inhibitor, liraglutide (Victoza or other GLP-1 agonists), metformin, canagliflozin (Invokana or other SGLT2 inhibitors) at time of screening
  19. Subject has a history of visual impairment which would not allow subject to participate in the study and perform all study procedures safely, as determined by the investigator
  20. Subject has elective surgery planned that requires general anesthesia during the course of the study
  21. Subject has a sickle cell disease, hemoglobinopathy; or has received red blood cell transfusion or erythropoietin within 3 months prior to time of screening
  22. Subject plans to receive red blood cell transfusion or erythropoietin over the course of study participation
  23. Subject diagnosed with current eating disorder such as anorexia or bulimia
  24. Subject has been diagnosed with chronic kidney disease that results in chronic anemia
  25. Subject has a hematocrit that is below the normal reference range of lab used.
  26. Subject is on dialysis
  27. Subject has serum creatinine of >2 mg/dL.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: NVT
  • Interventioneel model: Opdracht voor een enkele groep
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Hybrid closed loop
All subjects will be wearing the MMT-670G insulin pump, using it with the closed loop algorithm
Algoritme met gesloten lus
Andere namen:
  • MMT-670G

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Age 2-13 Years Old Subjects Change in A1C
Tijdsspanne: Baseline and end of 3-month study period
Descriptive analysis of change in A1C from baseline to end of 3-month study period
Baseline and end of 3-month study period

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Age 2-13 Years Old Subjects Mean Change in % of Time in Euglycemia (70-180 mg/dL)
Tijdsspanne: baseline and 3 months
mean change in % of time in Euglycemia (70-180 mg/dL) from baseline to 3 months study period
baseline and 3 months
Age 2-13 Years Old Subjects Mean Change in % of Time in Hyperglycemia (> 180 mg/dL)
Tijdsspanne: baseline and 3 months
mean change in % of time in hyperglycemia (> 180 mg/dL) from baseline to 3 months study period
baseline and 3 months
Age 2-13 Years Old Subjects Mean Change in % of Time in Hypoglycemia (<70 mg/dL)
Tijdsspanne: baseline and 3 months
mean change in % of time in hypoglycemia (< 70 mg/dL) from baseline to 3 months study period
baseline and 3 months
Age 2-13 Years Old - Number of Severe Hypoglycemic Event
Tijdsspanne: 3 months
Number of severe hypoglycemic events occurred during 3-month study period.
3 months
Age 2-13 Years Old - Number of Diabetic Ketoacidosis (DKA) Event
Tijdsspanne: 3 months
Number of Diabetic Ketoacidosis (DKA) events occurred during 3-month study period.
3 months
Age 7-13 Years Old Subjects PLGM Performance - Event Rate Without Hypoglycemia at YSI-FST <=65 mg/dL
Tijdsspanne: Up to 12 hours after the start of PLGM period
Event rate without Hypoglycemia at YSI-FST <=65 mg/dL among 105 subjects who underwent the PLGM experiments. The event rate without hypoglycemia is the number of experiments without hypoglycemia/total number of experiments and hypoglycemic events are defined based on the occurrence of 2 or more continuous YSI-FST <= 65mg/dL during in-clinic procedures.
Up to 12 hours after the start of PLGM period

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

18 april 2016

Primaire voltooiing (Werkelijk)

28 november 2018

Studie voltooiing (Werkelijk)

1 februari 2021

Studieregistratiedata

Eerst ingediend

16 januari 2016

Eerst ingediend dat voldeed aan de QC-criteria

16 januari 2016

Eerst geplaatst (Schatting)

21 januari 2016

Updates van studierecords

Laatste update geplaatst (Werkelijk)

26 januari 2022

Laatste update ingediend die voldeed aan QC-criteria

24 januari 2022

Laatst geverifieerd

1 januari 2022

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren